RBC Capital Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Cuts Target Price to $165

Moomoo NewsJan 7 09:31 ET · Ratings

RBC Cuts Price Target on Sarepta Therapeutics to $165 From $182, Keeps Outperform Rating

MT NewswiresJan 7 07:31 ET · Ratings

BofA Securities Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $217

Moomoo NewsJan 6 19:32 ET · Ratings

Sarepta Therapeutics (SRPT) Gets a Buy From Bank of America Securities

TipRanksJan 6 19:20 ET · Ratings

Sarepta Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

BusinesswireJan 6 08:30 ET

Sarepta Therapeutics (NASDAQ:SRPT) Delivers Shareholders Respectable 18% CAGR Over 3 Years, Surging 4.2% in the Last Week Alone

Simply Wall StJan 6 08:17 ET